Issue #45 — March 30, 2026
A decade after the Nobel Prize-winning discovery that molecular scissors could edit any gene in any living thing, CRISPR has transformed from a breathtaking idea into a working medicine — and a profound responsibility.
READ MORE →In 2012, Jennifer Doudna and Emmanuelle Charpentier published a paper describing a bacterial immune system that could, with extraordinary precision, cut DNA at any sequence the researchers specified. The scientific community immediately understood the implications. Within months, labs worldwide were using CRISPR-Cas9 to edit genes in human cells, mice, pigs, and corn. The Nobel Prize came in 2020. The first approved CRISPR therapy — Casgevy, for sickle cell disease — followed in late 2023.
Casgevy, developed jointly by Vertex Pharmaceuticals and CRISPR Therapeutics, received FDA approval in December 2023, marking a historic first: a CRISPR-based medicine available to patients. The therapy works by editing patients' own stem cells to reactivate fetal hemoglobin, bypassing the defective adult hemoglobin that causes sickle cell crises. Early trial data showed 97% of patients remained pain-crisis-free for over a year post-treatment — compared to roughly 45% on the best available standard care.
"We have moved from the question of 'can we edit the genome?' to 'how do we edit it safely and equitably?' — and those are very different conversations." — Dr. Fyodor Urnov, UC Berkeley
CRISPR-Cas9 cuts both strands of the DNA double helix, which is powerful but can introduce errors at the cut site. The field has since developed more precise successors. Base editing, pioneered by David Liu at the Broad Institute, chemically converts one DNA letter into another without cutting the strand at all. Prime editing — described as a "search and replace" for DNA — can insert, delete, or swap sequences with even greater fidelity. In 2025, the first base editing clinical trial for T-cell leukemia reported that 3 of 3 patients achieved complete remission.
As of early 2026, over 90 CRISPR-based therapies are in clinical trials globally. Targets include:
Most current therapies require removing cells from the patient, editing them in the lab, then reinfusing them — an ex vivo approach that is expensive and technically demanding. The next frontier is in vivo editing: delivering CRISPR machinery directly into the body, to the target organ, via lipid nanoparticles or engineered viruses. Intellia Therapeutics' NTLA-2001, a single-injection in vivo CRISPR therapy for TTR amyloidosis, showed 93% reduction in the disease-causing protein after one dose in Phase 1 trials — a result described by clinicians as "unprecedented."
Ten years on, CRISPR has delivered on its early promise — not as a silver bullet, but as a genuine new class of medicine, one that treats root causes rather than symptoms. The scissors have become a scalpel.
A handful of rare genetic diseases that once meant a short, painful life now have one-time treatments that work. The stories behind the data reveal both the miracle of gene therapy and the impossible economics surrounding it.
READ MORE →ADA-SCID — adenosine deaminase deficiency severe combined immunodeficiency, commonly called "bubble boy disease" — leaves children with no functional immune system. Without treatment, even a common cold can kill. In 2016, the EMA approved Strimvelis, a gene therapy that corrects the defective gene in the patient's own bone marrow stem cells. Efficacy: 100% of treated patients survived disease-free at five years of follow-up. It was described by immunologists as a functional cure.
Spinal muscular atrophy (SMA), the leading genetic cause of infant mortality, is caused by a missing or mutated SMN1 gene. Without the survival motor neuron protein it encodes, motor neurons die and patients lose the ability to move, swallow, and breathe. Zolgensma, a gene therapy from Novartis approved in 2019, delivers a working copy of SMN1 via a single intravenous infusion. Newborns treated before symptom onset — identified via expanded newborn screening — are reaching developmental milestones indistinguishable from unaffected peers. A disease that once meant ventilator dependency by age two is, in some cases, invisible.
"These children are running, climbing, going to school. Ten years ago, none of them would have been here." — Dr. Basil Darras, Boston Children's Hospital
Hemophilia B, caused by a deficient clotting factor IX gene, has been a gene therapy target since the 1990s. The journey illustrates both the promise and the patience gene medicine requires. Etranacogene dezaparvovec (Hemgenix), approved by the FDA in November 2022, delivers a high-activity version of the factor IX gene via a single infusion. Patients who previously needed regular infusions of clotting factor — or faced life-threatening bleeds — can maintain near-normal clotting for years on a single dose. The therapy costs $3.5 million — the most expensive drug in history at its launch, though health economists calculate it is cost-effective against a lifetime of treatment.
Gene therapies are, almost by definition, expensive. They are bespoke biological medicines, manufactured in small batches, after decades of research. Their developers argue the economics make sense: one treatment replacing a lifetime of management. But the structure of healthcare systems — built around annual costs, not one-time cures — means the economics are genuinely difficult. In the US, few insurers have frameworks to pay $2-4 million upfront for a cure. In Europe, pay-for-performance models — where the manufacturer refunds costs if the therapy doesn't work long-term — are emerging. The access gap between wealthy and developing nations is vast and growing.
The pipeline includes treatments for Duchenne muscular dystrophy (conditional FDA approval granted in 2023), Fabry disease, Gaucher disease, and multiple forms of inherited blindness. Each approval creates a new template — clinical, regulatory, economic — for the next. Gene therapy is no longer a hypothesis. It is a genre of medicine, still in its early chapters.
CRISPR is quietly transforming agriculture — creating crops that resist drought, pests, and disease without introducing foreign DNA. The regulatory and political battles over what counts as "GMO" are reshaping global food policy.
READ MORE →In 2021, Japanese regulators approved the world's first CRISPR food product: a tomato with reduced GABA degradation, resulting in higher concentrations of the calming neurotransmitter. Sold in Japan since 2022, Sanatech's "Sicilian Rouge High GABA" tomato is marketed as a wellness food. It is not a GMO in the traditional sense — no foreign DNA was inserted; a single gene was deactivated. This distinction — editing versus transgenics — is driving a global regulatory rethink.
In the United States, the USDA ruled in 2018 that CRISPR crops that could have occurred naturally through conventional breeding do not require special regulation. The EU took a far more restrictive stance until July 2023, when the European Commission proposed exempting certain gene-edited crops from GMO regulations. The UK, post-Brexit, passed the Precision Breeding Act in 2023, creating a faster approval path. The divide is partly scientific, partly cultural — and has enormous consequences for which crops reach farmers' fields and when.
"We are not moving genes between species. We are making the same changes that nature and traditional breeders have made for centuries — just precisely, and in months rather than decades." — Dr. Joyce Van Eck, Boyce Thompson Institute
The most urgent application is climate adaptation. Researchers have used CRISPR to:
One of the holy grails of agricultural biotech is extending nitrogen fixation — currently limited to legumes and a few other plants — to staple cereals like wheat, rice, and corn. These crops require massive nitrogen fertilizer inputs, responsible for approximately 1% of global energy consumption and significant greenhouse gas emissions. Researchers at the University of Nottingham and a team at the Innovative Genomics Institute are attempting to engineer the symbiotic relationship between nitrogen-fixing bacteria and plant roots into non-legume crops. It is among the most complex gene engineering challenges ever attempted.
Global population is projected to reach 9.7 billion by 2050. Climate change is reducing agricultural productivity in the tropics and subtropics. Gene editing is not a complete solution — soil health, water infrastructure, and distribution systems matter enormously — but it is a tool with genuine potential to maintain or improve yields as conditions shift. The question is whether the regulatory, political, and cultural frameworks will allow it to reach farmers, particularly in the regions that need it most.
He Jiankui edited the germline of twin girls in 2018 and went to prison. But the question he raised has not gone away: if we can edit heritable traits, who decides which traits to edit — and who gets to decide what counts as disease, difference, or enhancement?
READ MORE →In November 2018, biophysicist He Jiankui announced at an international genome editing summit in Hong Kong that he had used CRISPR to edit the CCR5 gene in embryos that became twin girls, Lulu and Nana. The edit was designed to confer resistance to HIV. He did it covertly, without adequate regulatory oversight or informed consent procedures that met international standards. The scientific community's response was near-universal condemnation. He was sentenced to three years in prison. The twins' identities remain protected. And the gene editing community, shaken, convened the International Commission on the Clinical Use of Human Germline Genome Editing.
Most gene therapies approved or in trials today are somatic — they edit cells in the body of one patient, and those edits are not inherited. Germline editing is different: changes to embryo, egg, or sperm cells are passed to all subsequent generations. This is the dividing line between treating a patient and changing the human lineage. The 2020 international commission concluded that germline editing should not proceed to clinical use until robust societal debate, oversight mechanisms, and technical safety standards exist — a position that remains the consensus of major scientific bodies.
"The question is not whether we should ever edit the germline. It is whether we have the wisdom to decide, as a species, when and for what." — Commission on Human Germline Genome Editing, 2020
The gene editing debate intersects uncomfortably with disability rights. Advocates argue that the medical framing of genetic differences as "defects to be corrected" reflects a limited view of human variation and worth. Deaf communities have, in some cases, opposed prenatal genetic testing aimed at preventing deafness, arguing that Deaf culture is not a disorder. The same tension applies to achondroplasia (dwarfism), Down syndrome, and other conditions that are simultaneously medical challenges and identities. Who decides which genes are diseases, and by whose standard?
The line between treating disease and enhancing capability is blurrier than it appears. Sickle cell therapy restores function most people have — that is treatment. But what about editing for increased muscle efficiency, higher pain tolerance, or disease resistance beyond what any human currently possesses? These are enhancement. The boundaries are contested. Some bioethicists argue the distinction is philosophically incoherent — that preventing suffering is always good, regardless of what we call it. Others warn that a market in genetic enhancement will deepen inequality, creating a world where the wealthy purchase biological advantages for their children that compound across generations.
Gene editing oversight is national, not global. China's regulatory response to He Jiankui tightened significantly after the scandal. The US, EU, and UK each have different frameworks. Nations with weaker oversight remain potential venues for what critics call "gene editing tourism." The WHO's expert advisory committee issued recommendations in 2021 for a global registry of human genome editing research. As of 2026, implementation remains uneven. The technology has outpaced the governance — and the gap is not closing.
We are, for the first time in history, a species that can deliberately shape its own biology. That power demands not just scientific competence but moral imagination — the capacity to ask not only what we can do, but what kind of world we are choosing to build.